442 related articles for article (PubMed ID: 33293830)
1. Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data.
Loscocco GG; Guglielmelli P; Vannucchi AM
Onco Targets Ther; 2020; 13():12367-12382. PubMed ID: 33293830
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
3. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
4. Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.
Loscocco GG; Coltro G; Guglielmelli P; Vannucchi AM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440731
[TBL] [Abstract][Full Text] [Related]
5. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Ferreira Cristina S; Polo B; Lacerda JF
Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
[TBL] [Abstract][Full Text] [Related]
6. Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.
Zhou A; Afzal A; Oh ST
Curr Hematol Malig Rep; 2017 Oct; 12(5):397-405. PubMed ID: 28948488
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
8. Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M; Robinson D; Wu YM; Qin T; Pettit K; Li Q; Luker G; Sartor M; Chinnaiyan A; Talpaz M
Clin Cancer Res; 2024 May; 30(9):1972-1983. PubMed ID: 38386293
[TBL] [Abstract][Full Text] [Related]
9. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
10. Recent insights regarding the molecular basis of myeloproliferative neoplasms.
Jang MA; Choi CW
Korean J Intern Med; 2020 Jan; 35(1):1-11. PubMed ID: 31778606
[TBL] [Abstract][Full Text] [Related]
11. Targeted deep sequencing in polycythemia vera and essential thrombocythemia.
Tefferi A; Lasho TL; Guglielmelli P; Finke CM; Rotunno G; Elala Y; Pacilli A; Hanson CA; Pancrazzi A; Ketterling RP; Mannarelli C; Barraco D; Fanelli T; Pardanani A; Gangat N; Vannucchi AM
Blood Adv; 2016 Nov; 1(1):21-30. PubMed ID: 29296692
[TBL] [Abstract][Full Text] [Related]
12. Mutational profiling in myelofibrosis: implications for management.
Bose P; Verstovsek S
Int J Hematol; 2020 Feb; 111(2):192-199. PubMed ID: 31630335
[TBL] [Abstract][Full Text] [Related]
13. Myeloproliferative Neoplasms with Monocytosis.
Morsia E; Gangat N
Curr Hematol Malig Rep; 2022 Feb; 17(1):46-51. PubMed ID: 34773576
[TBL] [Abstract][Full Text] [Related]
14. Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Easwar A; Siddon AJ
Life (Basel); 2021 Oct; 11(11):. PubMed ID: 34833034
[TBL] [Abstract][Full Text] [Related]
15. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
17. Genetic Risk Assessment in Myeloproliferative Neoplasms.
Tefferi A; Vannucchi AM
Mayo Clin Proc; 2017 Aug; 92(8):1283-1290. PubMed ID: 28778261
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
19. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].
Tan YX; Xu N; Huang JX; Wu WE; Liu L; Zhou LL; Liu XL; Yin CX; Xu D; Zhou X
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):576-582. PubMed ID: 32810965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
